| Zhang, Mingzhi |
NCT04490590: A Clinical Trial of Chidamide Combined With Etoposide in Relapsed or Refractory NK/T-cell Lymphoma |
|
|
| Recruiting | 4 | 30 | RoW | Chidamide+ Etoposide | Mingzhi Zhang | NK/T-Cell Lymphoma | 10/20 | 10/21 | | |
NCT04083066: Open Randomized Prospective Clinical Study of R-FPD Versus R-MAD Regimen in the Treatment of Primary Central Nervous System Lymphoma |
|
|
| Recruiting | 4 | 20 | RoW | rituximab in combination with methotrexate, cytarabine and dexamethasone | Mingzhi Zhang | Primary Central Nervous System Lymphoma | 04/23 | 04/24 | | |
RUE-DDGP, NCT04999878: A Prospective Clinical Study of Ruxolitinib and Etoposide Combined With DDGP Regimen () in Induction Therapy of T/NK Cell Lymphoma-associated Hemophagocytic Syndrome. |
|
|
| Recruiting | 4 | 30 | RoW | Ruxolitinib, Etoposide, Dexamethasone, Gemcitabine, Pegaspargase, cis-platinum | Zhengzhou University | Hemophagocytic Syndrome, T/NK-Cell Lymphoma | 06/23 | 06/24 | | |
| Completed | 3 | 410 | Europe, US, RoW | HLX04-O, ranibizumab | Shanghai Henlius Biotech | Age Related Macular Degeneration | 12/24 | 12/24 | | |
NCT04578613: ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL |
|
|
| Recruiting | 3 | 218 | RoW | ICP-022, Chlorambucil, Rituximab | Beijing InnoCare Pharma Tech Co., Ltd. | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 12/24 | 06/25 | | |
NCT06717152: Efficacy and Safety of SJP-0132 Eye Drops in Chinese Patients With Dry Eye Disease |
|
|
| Recruiting | 3 | 400 | RoW | SJP-0132, Placebo | Senju Pharmaceutical Science & Technology (Beijing) Co., Ltd., Senju Pharmaceutical Co., Ltd. | Dry Eye | 07/25 | 08/25 | | |
NCT03934567: A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma |
|
|
| Recruiting | 2 | 96 | RoW | Abexinostat | Xynomic Pharmaceuticals, Inc. | Lymphoma, Follicular | 02/24 | 09/24 | | |
NCT04586478: Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma |
|
|
| Recruiting | 2 | 60 | RoW | single dose of CNCT19 | Juventas Cell Therapy Ltd. | Non-Hodgkin's Lymphoma | 12/24 | 09/25 | | |
NCT03936153: Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) |
|
|
| Recruiting | 2 | 170 | RoW | abexinostat | Xynomic Pharmaceuticals, Inc. | Diffuse Large B-cell Lymphoma (DLBCL) | 12/24 | 05/25 | | |
NCT06093841: Relmacabtagene Autoleucel as Second-Line Therapy in Adult Patients With Aggressive B-cell NHL |
|
|
| Not yet recruiting | 2 | 46 | RoW | Relmacabtagene Autoleucel, JWCAR029, Fludarabine, Cyclophosphamide | Shanghai Ming Ju Biotechnology Co., Ltd. | Lymphoma, Large B-Cell, Diffuse, Follicular Lymphoma Grade 3B, High-grade B-cell Lymphoma, Mediastinal B-Cell Diffuse Large Cell Lymphoma | 08/24 | 02/27 | | |
NCT04831658: A Prospective Clinical Study of BTK Inhibitor, PD-1 and Formustine in the First-line Treatment of Primary Central Nervous System Lymphoma |
|
|
| Recruiting | 1/2 | 40 | RoW | the dose-escalation phase, The extended treatment phase | Mingzhi Zhang | Primary Central Nervous System Lymphoma | 09/23 | 09/24 | | |
NCT06683885: A Prospective Clinical Study of the Combination Therapy of Obutinib or Decitabine with Rituximab, Cyclophosphamide, and Prednisone for the Primary Treatment of Elderly Patients with Newly Diagnosed Diffuse Large B-cell Lymphoma |
|
|
| Recruiting | 1/2 | 80 | RoW | Obutinib or Decitabine, Rituximab, Compound Cyclophosphamide Tablets and Prednisone | Mingzhi Zhang | Newly Diagnosed Diffuse Large B-cell Lymphoma | 05/26 | 05/26 | | |
NCT05485753: A Study of GNC-038, a Tetra-specific Antibody, in Patients With Central Nervous System Lymphoma (PCNSL) and Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL) |
|
|
| Recruiting | 1/2 | 33 | RoW | GNC-038 | Sichuan Baili Pharmaceutical Co., Ltd., SystImmune Inc., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Primary Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma | 05/25 | 05/25 | | |
NCT05698147: Selinexor in Combination With MTX+Ritu to Treat R/R CNSL |
|
|
| Recruiting | 1/2 | 30 | RoW | Selinexor, ATG-010, Rituximab, RiTUXimab Injection, Methotrexate, MTX | Tong Chen, MD, Antengene Corporation | Central Nervous System Lymphoma | 06/26 | 12/26 | | |
ELEVATION, NCT05800977: A Study of C-CAR039 (Prizloncabtagene Autoleucel) in Patients with Relapsed/Refractory Large B-Cell Lymphoma |
|
|
| Recruiting | 1/2 | 112 | RoW | Prizloncabtagene autoleucel, C-CAR039 | Shanghai AbelZeta Ltd. | Relapsed/Refractory Large B-Cell Lymphoma | 10/25 | 12/27 | | |
NCT04480788: CD7-CART in the Treatment of r / r CD7 Positive Hemolymph System Malignancies on Increasing Dose and Open Label Study |
|
|
| Recruiting | 1 | 9 | RoW | T cell injection targeting CD7 chimeric antigen receptor | PersonGen BioTherapeutics (Suzhou) Co., Ltd., The First Affiliated Hospital of Zhengzhou University | T Lymphoblastic Leukemia/Lymphoma, Extramedullary NK-T-cell Lymphoma, Nasal Type, Peripheral T-cell Lymphoma, Nonspecific, Angioimmunoblastic T-cell Lymphoma, Enteropathy-Associated T-Cell Lymphoma, Anaplastic Large Cell Lymphoma, ALK-negative, T-cell Lymphoblastic Leukemia | 08/22 | 08/22 | | |
PG-CART-07-001, NCT05170568: PA3-17 Injection Treatment of Adult Patients With CD7-positive Relapsed/Refractory Lymphoid Hematologic Malignancies |
|
|
| Recruiting | 1 | 22 | RoW | T cell injection targeting CD7 chimeric antigen receptor, PA3-17 injection | PersonGen BioTherapeutics (Suzhou) Co., Ltd., The First Affiliated Hospital of Zhengzhou University, Peking University People's Hospital, Union Hospital, affiliated with TongJi Medical College, HuaZhong University of Science and Technology, Hematology Hospital of Chinese Academy of Medical Sciences (Hematology Research Center of Chinese Academy of Medical Sciences), First Affiliated Hospital of Zhejiang University School of Medicine | CD7-positive Relapsed/Refractory Lymphoid Hematologic Malignancies | 12/22 | 12/24 | | |
| Recruiting | 1 | 152 | RoW | Recombinant CD20 monoclonal antibody-MMAE conjugte for injection, TRS005 | Zhejiang Teruisi Pharmaceutical Inc. | CD20-positive B-cell Non-Hodgkin Lymphoma | 12/23 | 12/24 | | |
NCT06647329: CAR-T Technology for Recurrent/Refractory Malignant Hematological and Lymphatic Tumors |
|
|
| Not yet recruiting | 1 | 30 | RoW | CAR-T Therapy | Mingzhi Zhang | CAR-T Cell Therapy, Lymphomas | 12/25 | 12/26 | | |
NCT05979792: Clinical Study of CD7 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory CD7-positive Peripheral T Cell Lymphoma |
|
|
| Not yet recruiting | 1 | 35 | RoW | CAR-T Therapy | Zhao Weili | Peripheral T Cell Lymphoma | 08/25 | 12/25 | | |
NCT05167630: Prognosis Factors in Patients With Primary Central Nervous System Lymphoma |
|
|
| Recruiting | N/A | 40 | RoW | prognostic marker | Zhengzhou University | PCNSL, Survival Analysis | 12/21 | 12/21 | | |
